A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 90 sites in 15 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 3rd largest by enrollment, is one of 4 that started in 2022, is one of 19 in phase 3, and was the 18th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2022.
This study's enrollment of 307 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 15th largest by enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2022, is one of 62 in phase 3, and was the 105th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.
Other: Placebo (matched to ELX/TEZ/IVA) · Other: Placebo (matched to IVA)
Participants 6 to less than (\<) 12 years of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination (FDC) tablets for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Placebo matched to ELX/TEZ/IVA for oral administration.
Placebo matched to IVA for oral administration.
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Week 24
Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline Through Week 24
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline Through Week 24
Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
Time frame: From Baseline at Week 24
Absolute Change in Weight
Time frame: From Baseline at Week 24
Number of Pulmonary Exacerbations (PEx)
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline Through Week 24
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 28
This study was conducted in cystic fibrosis (CF) participants aged 6 years and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.
| Milestone | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Started | 102 | 205 |
| Completed | 102 | 197 |
| Not completed | 0 | 8 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 2 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted FEV1 | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | -0.4 (-2.0 to 1.3) | 8.9 (7.7 to 10.0) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Absolute Change in Sweat Chloride (SwCl) | 0.5 (-2.6 to 3.6) | -27.8 (-30.0 to -25.6) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score | -2.0 (-5.2 to 1.3) | 17.5 (15.2 to 19.8) |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
| kg/m^2 | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Absolute Change in Body Mass Index (BMI) | 0.35 (0.16 to 0.53) | 0.81 (0.68 to 0.94) |
| kilogram (kg) | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Absolute Change in Weight | 1.2 (0.6 to 1.7) | 2.4 (2.1 to 2.8) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| PEx events | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Number of Pulmonary Exacerbations (PEx) | 40 | 21 |
| Participants | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Participants with TEAEs | 97 | 193 |
| Participants with SAEs | 15 | 18 |
Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/102 (0%) | 15/102 (14.7%) | 86/102 (84.3%) |
| ELX/TEZ/IVA | 1/205 (0.5%) | 18/205 (8.8%) | 164/205 (80%) |
| Event | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 13/102 | 5/205 |
| Stress cardiomyopathyCardiac disorders | 1/102 | 0/205 |
| Drug intoleranceGeneral disorders | 1/102 | 0/205 |
| Renal colicRenal and urinary disorders | 1/102 | 0/205 |
| Bronchopulmonary aspergillosis allergicInfections and infestations | 0/102 | 2/205 |
| Abdominal painGastrointestinal disorders | 0/102 | 1/205 |
| PancreatitisGastrointestinal disorders | 0/102 | 1/205 |
| SubileusGastrointestinal disorders | 0/102 | 1/205 |
| Cholecystitis acuteHepatobiliary disorders | 0/102 | 1/205 |
| GastroenteritisInfections and infestations | 0/102 | 1/205 |
| Event | Placebo | ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 36/102 | 28/205 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/102 | 36/205 |
| RashSkin and subcutaneous tissue disorders | 1/102 | 45/205 |
| NasopharyngitisInfections and infestations | 20/102 | 42/205 |
| HeadacheNervous system disorders | 13/102 | 37/205 |
| PyrexiaGeneral disorders | 14/102 | 27/205 |
| Abdominal painGastrointestinal disorders | 13/102 | 17/205 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 13/102 | 20/205 |
| DiarrhoeaGastrointestinal disorders | 10/102 | 26/205 |
| COVID-19Infections and infestations | 10/102 | 19/205 |
All participants who received at least one dose of the study drug were included in the baseline analysis.
| Age, Continuous(years) | Placebo | ELX/TEZ/IVA | Total |
|---|---|---|---|
| Mean | 33.9 ± 16.4 | 33.3 ± 15.9 | 33.5 ± 16.0 |
| Sex: Female, Male(Participants) | Placebo | ELX/TEZ/IVA | Total |
|---|---|---|---|
| Female | 52 | 113 | 165 |
| Male | 50 | 92 | 142 |
| Race/Ethnicity, Customized(Participants) | Placebo | ELX/TEZ/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 8 | 11 |
| Not Hispanic or Latino | 88 | 171 | 259 |
| Not Collected per Local Regulations | 11 | 26 | 37 |
| Race/Ethnicity, Customized(Participants) | Placebo | ELX/TEZ/IVA | Total |
|---|---|---|---|
| White | 86 | 172 | 258 |
| Asian | 2 | 4 | 6 |
| Other | 1 | 3 | 4 |
| Not Collected per Local Regulations | 12 | 26 | 38 |
| White, Asian | 1 | 0 | 1 |
| Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(percent predicted FEV1) | Placebo | ELX/TEZ/IVA | Total |
|---|---|---|---|
| Mean | 68.1 ± 18.1 | 67.5 ± 17.6 | 67.7 ± 17.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from May 2022 to primary completion in Jul 2023, 13 months.
Results were first posted in Aug 2024, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 13 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →